Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) is devoted to deepening reform based on innovation, integration and internationalization and adhering to the principle of openness and cooperation.
It has been a leading player in development of the pharmaceutical industry in Shanghai in recent years.
Improve market-oriented management system
By constantly improving the system pertaining to state-owned assets supervision and marketization operations, SPH has built itself into an open and innovative enterprise. Thanks to the system, it has made key progress in new medicine development.
The company also improved its management and control system which included drafting a strengthened business enforcement strategy as well as performance evaluation and salary distribution.
It also cooperated with more than ten foreign enterprises in strategy, equity and business.
In 2020, it reached agreements with Stemirna Therapeutics, CanSino Biologics Inc. and Zhejiang Jiuzhou Pharmaceutical Co., Ltd on research and development of the COVID-19 mRNA vaccines, vaccine production, capacity expansion, material storage and supply chain construction as well as development of advanced generic drugs and modified new drugs.
The company signed contracts with BIOCAD, Russia's largest bio-pharmaceutical, in 2019, to promote biological medicine development with $400 million of investment. At present, registration of the first six kinds of biological medicines is underway in China.
Coordinated development of production, education and research is also highly valued by SPH.
It has carried out cooperation with more than 20 scientific research institutions and universities on new drug development and clinical trials.
The company invested more than 1.5 billion yuan ($231.3 million) in such cooperation in 2019 and launched an innovation incubation platform with the School of Medicine of Shanghai Jiao Tong University.
Deepen recruitment, incentive systems
Talent has been hailed a top resource of innovation. Therefore, SPH promoted recruitment, appointment and cultivation of talents and development of an incentive mechanism to boost innovation.
The company has introduced talents expert in high-tech research and development and marketing in recent years, which improved investor relations management and drug development capacity.
It also launched a series of training courses to cultivate new employees and improve managers' abilities.
Optimize allocation of production
SPH sorted its production base into several categories and promoted green and intelligent applications in its workshops, industrial parks, products and supply chains.
It is now building an innovative base of biological medicine which includes infrastructure for clinical research, testing and mass production and a service platform. A total of more than 7 billion yuan is earmarked for the project.
In addition, the company plans to invest 6 billion yuan in construction of the Baoshan Pharmaceutical Industrial Park, which will include a super workshop and a smart logistics center.
SPH will continue to deepen SOE reform and stick to innovation-driven development to evolve into a competitive pharmaceutical enterprise and contribute to development of Shanghai as a science and technology innovation center.
A view of Shanghai Pharmaceuticals Holding Co., Ltd. [Photo/sasac.gov.cn]
An SPH researcher at work [Photo/sasac.gov.cn]
(Executive editor: Wang Ruoting)